CA-VERIMATRIX
30.6.2020 17:47:05 CEST | Business Wire | Press release
Verimatrix , (Paris:VMX), the leader in powering the modern connected world with people-centered security, today announced its second virtual event this year designed to showcase how the global expansion of video, applications and connected devices has multiplied today’s attack surfaces. The Verimatrix Summer Summit consists of webcasts and private meetings taking place Wednesday, July 8, and Thursday, July 9, 2020.
“Now more than ever, organizations need to provide their customers with compelling experiences – but those experiences must be protected,” said Asaf Ashkenazi, COO of Verimatrix. “The Verimatrix Summer Summit will showcase why security matters more than ever -- and why in today’s modern connected world, security should be intuitive, user-friendly, and fast."
To kick off the Summit, Verimatrix Chairman and CEO Amedeo D’Angelo will underscore the importance of reliable and trustworthy security in the high-growth areas of video content, mobile applications and connected devices.
Verimatrix Virtual Summit Experience
Trusted Security: What it Means to Be a Trusted Security Partner
Wednesday, July 8, 6:30am PT / 1:30pm GMT
Amedeo D’Angelo, Chairman and CEO of Verimatrix, will explore what it means to be a trusted security partner, how the global expansion of video, applications and connected devices has multiplied today’s attack surfaces, and why the future of scalable, cost-effective SaaS security in the cloud is so exciting.
Every Second Counts: Building Better Sports Fan Experiences Through Secure Mobile Apps and Connected Game Play
Wednesday, July 8, 7:00am PT / 2:00pm GMT
Produced and moderated by SportsPro, this webinar will showcase how today’s technological change is forever altering fan perceptions and demands for the sporting experience. Franchises who provide trusted gameday ecosystems will win over the hearts, minds and pocketbooks of fans – while preserving valuable revenue streams. Panelists include Leanne Johnson, VP of Digital for the Milwaukee Bucks and Lucas von Cranach, CEO and Founder of Onefootball. Eoin Connolly, Editor-At-Large for SportsPro, will moderate.
Cloud Speed Ahead: Unlocking New Opportunities with Secure Content Distribution
Wednesday, July 8, 8:00am PT / 3:00pm GMT
Produced by Omdia, this webinar will explore how content providers are efficiently setting up new distribution channels around the world by maximizing novel OTT direct-to-consumer strategies without breaking the bank. Allen Tatara, Sr. Manager, Webinar Events at Omdia will moderate. Panelists will include Geoff Stedman, Enterprise Media Strategist at AWS Elemental, Asaf Askenazi, Chief Operating Officer at Verimatrix and Merrick Kingston, Associate Director at Omdia.
Apps Under Siege: Understanding Today’s Threats to Web/Mobile Applications and How to Defend Your IP While Safeguarding Customers
Wednesday, July 8, 11:30am PT / 6:30pm GMT
Experts from Jscrambler and Verimatrix will discuss how the lack of application protection is a giant blind spot and source of risk for many companies. Whether they want to acknowledge it or not, virtually every company today is in the app business. This webinar will reveal how to protect apps from harm without degrading the user experience. Lu Bolden, Chief Revenue Officer at Verimatrix will moderate. Panelist will include Pedro Fortuna, Co-Founder & CTO at Jscrambler and Neal Michie, Director Product Management at Verimatrix.
Defend and Protect: How Cybercriminals Are Hacking Healthcare Workflows & How to Stop Them
Thursday, July 9, 8:00am PT / 3:00pm GMT
Moderated by Adam Turinas, this panel session will explore how cybercriminals can cripple healthcare workflows. It will uncover how tele-health platforms, apps and devices can be hacked relatively easily, share examples of breaches and review the latest security techniques. The results of a security effectiveness test of the world’s top 20 healthcare apps will be shared during the session. The webinar will be moderated by Adam Turinas, CEO & Founder of HealthLaunchpad. Panelists include John Ulett, CIO of CentraState Healthcare System, John Hendricks, CTO of Huntzinger Management Group, Brian Lawrence, Director Solution Engineering at NowSecure and Asaf Ashkenazi, Chief Operating Officer at Verimatrix.
Churning It Around: How to Identify and Retain At-Risk Video and Internet Service Subscribers Using Data Stories
Thursday, July 9, 9:00am PT / 4:00pm GMT
This panel will explore how security vendors and systems integrators are working with operators to utilize the latest data harvesting & analytics tools to surface subscriber profitability stories. This can lead to actionable insights powerful enough to boost consumption rates, reduce churn and increase ARPU – all of which are especially critical in a climate of tight pocketbooks caused by COVID-19. Moderated by Sebastian Braun, Director Product Management at Verimatrix, this panel will feature Luc Bleylevens, Senior Product Director, Subscriber Retention Management at Cleeng, Daragh O Brien, CEO & Managing Director of Castlebridge and Derek Harrar, CEO of Zodiac.
Adapt or Die: The Content Distribution Business Model in Flux
Thursday, July 9, 11:30am PT / 6:30pm GMT
Speakers from Xperi (TiVo) and 3Vision come together for this insightful session on the impact of COVID-19 on the traditional Hollywood business and their audiences. Topics to be explored include what’s changing within the content distribution business model and why, the shifting power of content producers, trends in security technologies and integration methods and more. Moderated by Lu Bolden, Chief Revenue Officer at Verimatrix, this webinar will feature Nic Wilson, Head of Customer Success at TiVo and Jack Davison, EVP of 3Vision.
To learn more about the Verimatrix Summer Summit, or register to attend any of the sessions go to www.summit.verimatrix.com .
About Verimatrix
Verimatrix (Euronext Paris: VMX) helps power the modern connected world with security made for people. We protect digital content, applications, and devices with intuitive, people-centered and frictionless security. Leading brands turn to Verimatrix to secure everything from premium movies and live streaming sports, to sensitive financial and healthcare data, to mission-critical mobile applications. We enable the trusted connections our customers depend on to deliver compelling content and experiences to millions of consumers around the world. Verimatrix helps partners get to market faster, scale easily, protect valuable revenue streams, and win new business. To learn more, visit www.verimatrix.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200630005500/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom